Serum concentration/dose ratio of topiramate during pregnancy
Version of Record online: 30 OCT 2008
Wiley Periodicals, Inc. © 2008 International League Against Epilepsy
Volume 50, Issue 3, pages 480–485, March 2009
How to Cite
Westin, A. A., Nakken, K. O., Johannessen, S. I., Reimers, A., Lillestølen, K. M. and Brodtkorb, E. (2009), Serum concentration/dose ratio of topiramate during pregnancy. Epilepsia, 50: 480–485. doi: 10.1111/j.1528-1167.2008.01776.x
- Issue online: 4 MAR 2009
- Version of Record online: 30 OCT 2008
- Accepted July 3, 2008; Early View publication October 30, 2008.
- Antiepileptic drugs;
- Drug monitoring;
- Pregnancy outcome
Purpose: To study the impact of pregnancy on the serum concentration/dose ratio (C/D-ratio) of topiramate (TPM).
Methods: Twelve women with epilepsy using TPM during pregnancy, and 15 pregnancies were studied. The main target variable was the C/D-ratio at baseline and during pregnancy. Additional variables were changes in TPM dose, concomitant use of other antiepileptic drugs, seizure frequency, and pregnancy outcome. Clinical and pharmacological data were obtained from the women's medical records.
Results: The average C/D-ratios in the second and third trimester were 30% (p = 0.002, n = 11) and 34% (p = 0.001, n = 8) lower than the baseline values, respectively. The interindividual variability was pronounced. Increased seizure frequency was common in pregnant women using TPM, but a correlation to the decline in TPM C/D-ratio could not be established from our data.
Discussion: Dose-corrected serum concentrations of TPM appear to decline gradually throughout pregnancy. The underlying mechanisms are not known. Increased glomerular filtration may play a major role. During pregnancy, therapeutic drug monitoring of TPM may be useful.